[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US20170266151A1 - Novel salts of 3-[(DIMETHYLAMINO)METHYL]-N--1-BENZOFURAN-2-CARBOXAMIDE, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same - Google Patents

Novel salts of 3-[(DIMETHYLAMINO)METHYL]-N--1-BENZOFURAN-2-CARBOXAMIDE, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same Download PDF

Info

Publication number
US20170266151A1
US20170266151A1 US15/508,609 US201515508609A US2017266151A1 US 20170266151 A1 US20170266151 A1 US 20170266151A1 US 201515508609 A US201515508609 A US 201515508609A US 2017266151 A1 US2017266151 A1 US 2017266151A1
Authority
US
United States
Prior art keywords
expressed
crystalline form
benzofuran
dimethylamino
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/508,609
Inventor
Marina GAILLARD
Philippe Letellier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
Original Assignee
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1458224A external-priority patent/FR3025197B1/en
Priority claimed from FR1458215A external-priority patent/FR3025196B1/en
Application filed by Pharmacyclics LLC filed Critical Pharmacyclics LLC
Publication of US20170266151A1 publication Critical patent/US20170266151A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01V—GEOPHYSICS; GRAVITATIONAL MEASUREMENTS; DETECTING MASSES OR OBJECTS; TAGS
    • G01V3/00—Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination, deviation
    • G01V3/14—Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination, deviation operating with electron or nuclear magnetic resonance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to novel salts of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide or hydrates or polymorphs thereof, methods for preparing the same as well as pharmaceutical compositions and uses thereof.
  • abexinostat 3-[(Dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide, also referred to as abexinostat, is a histone deacetylase (HDAC) inhibitor which is described in the patent application WO 2004/092116. It was shown to inhibit cell growth and induce apoptosis in tumor cells cultured in vitro, and inhibit tumor growth in viva in xenograft models (Buggy et al., Mol. Cancer Ther. 2006, 5 (5), 1309). Given its pharmacological profile, abexinostat is intended to be used in the treatment of cancer.
  • HDAC histone deacetylase
  • the present invention relates to novel salts of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide or hydrates or crystalline forms thereof, methods for preparing or using the same as well as pharmaceutical compositions containing the same.
  • the invention relates to salts of 3-[(dimethylamino) methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide of formula (I):
  • HA is naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, oxalic acid, benzenesulfonic acid, or sulfuric acid or hydrates thereof.
  • the present invention also relates to novel crystalline forms of the salts of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide of formula (I), methods for preparing the same as well as pharmaceutical compositions containing the same, and uses thereof.
  • the present invention relates to naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid oxalic acid, benzenesulfonic acid, or sulfuric acid salts of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide or one of the hydrates thereof, a method for preparing the same as well as pharmaceutical compositions containing the same, and uses thereof.
  • the invention relates to salts of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide of formula (Ia):
  • HA is naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, oxalic acid or benzenesulfonic acid.
  • the subject matter of the invention relates to the hydrogen sulfate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide of formula (Ib):
  • HA is sulfuric acid, as well as hydrates thereof.
  • the present invention also describes methods for producing salts of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide in well-defined and reproducible crystalline forms or hydrated crystalline forms, inhibiting very good stability compatible with the industrial constraints on preparation (in particular, drying) and storage of pharmaceutical compositions.
  • a crystalline form of the naphthalene-1,5-disulfonate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide produced using the method according to the invention which is characterized by a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees ⁇ 0.2°): 6.87; 10.71; 11.31; 13.97; 18.51; 21.49; 21.84; 24.56.
  • the crystalline form of the naphthalene-1,5-disulfonate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide carboxamide is characterized by the following diffraction lines: 6.87; 10.71; 11.31; 13.97; 18.51; 20.71; 21.18; 21.49; 21.84; 22.74; 24.56.
  • the crystalline form of the naphthalene-1,5-disulfonate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide is characterized by the powder X-ray diffraction diagram below, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees ⁇ 0.2°) and interplanar spacing d (expressed in ⁇ ):
  • the crystalline form of the naphthalene-1,5-disulfonate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide has also been characterized by solid state NMR spectroscopy and the 13 C CP/MAS (cross polarization/magic angle spinning) spectrum exhibits the following peaks (expressed in ppm ⁇ 0.2 ppm):
  • a crystalline form of the naphthalene-2-sulfonate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide produced using the method according to the invention which is characterized by a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed m degrees ⁇ 0.2): 8.92; 9.33; 10.85; 17.89; 19.79; 21.79; 26.39.
  • the crystalline form of the naphthalene-2-sulfonate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide is characterized by the following diffraction lines: 8.92; 9.33; 10.85; 11.78; 17.89; 19.79; 19.99; 21.79; 25.23; 26.39.
  • the crystalline form of the naphthalene-2-sulfonate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide is characterized by the powder X-ray diffraction diagram below, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees ⁇ 0.2) and interplanar spacing d (expressed in ⁇ ):
  • the crystalline form of the naphthalene-2-sulfonate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide has also been characterized by solid state NMR spectroscopy and the 13 C CP/MAS spectrum exhibits the following peaks (expressed in ppm ⁇ 0.2 ppm):
  • a crystalline form of the oxalate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide produced using the method according to the invention, which is characterized by a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees ⁇ 0.2): 9.11; 9.67; 16.39; 17.73; 18.49; 18.65; 18.79; 21.96; 22.39; 23.39; 26.76; 27.92; 30.72.
  • the crystalline form of the oxalate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide is characterized by the following diffraction lines: 9.11; 9.67; 16.39; 16.56; 17.73; 18.49; 18.65; 18.79; 20.35; 20.85; 21.00; 21.96; 22.39; 23.39; 23.91; 26.22; 26.76; 27.92; 30.72.
  • the crystalline form of the oxalate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide is characterized by the powder X-ray diffraction diagram below, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees ⁇ 0.2°) and of interplanar spacing d (expressed in ⁇ ):
  • a novel crystalline form of the benzenesulfonate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide produced using the method according to the Invention, which is characterized by a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees ⁇ 0.2°): 8.08; 10.03; 10.36; 13.63; 15.00; 16.19; 17.73; 17.90; 18.77; 19.77; 21.98; 22.45.
  • the crystalline form of the benzenesulfonate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide is characterized by the following diffraction lines: 8.08; 10.03; 10.36; 11.86; 12.66; 13.63; 15.00; 16.19; 16.39; 16.52; 17.73; 17.90; 18.77; 19.77; 20.20; 20.86; 21.11; 21.98; 22.45; 23.84; 26.13; 26.74; 27.44.
  • the crystalline form of the benzenesulfonate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide is characterized by the powder X-ray diffraction diagram below, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees ⁇ 0.2°) and of interplanar spacing d (expressed in ⁇ ):
  • the hydrate is a hemipentahydrate. In another embodiment, the hydrate is a hemiheptahydrate.
  • the hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide produced using the method according to the invention is characterized by a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees ⁇ 0.2°): 6.92; 9.01; 11.04; 13.87; 14.24; 14.89; 15.06; 17.34; 18.96; 20.05; 21.49; 24.34; 24.59; 25.19; 25.89.
  • the hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide is characterized by the following diffraction lines: 6.92; 9.01; 11.04; 11.82; 13.87; 14.24; 14.89; 15.06; 17.34; 18.96; 20.05; 20.84; 21.23; 21.49; 22.68; 22.85; 24.34; 24.59; 25.19; 25.89; 28.28.
  • the hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide is characterized by the powder X-ray diffraction diagram below, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees ⁇ 0.2°) and interplanar spacing d (expressed in ⁇ ):
  • the hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide has also been characterized by solid state NMR spectroscopy and the 13 C CP/MAS (cross polarization/magic angle spinning) spectrum exhibits the following peaks (expressed in ppm ⁇ 0.2 ppm):
  • the hemiheptahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide produced using the method according to the invention is characterized by a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees ⁇ 0.2°): 9.99; 10.67; 13.79; 13.92; 14.25; 14.67; 15.18; 16.21; 18.44; 18.82; 20.42; 21.71; 22.47; 23.30; 24.25.
  • the hemiheptahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide is characterized by the following diffraction lines: 9.99; 10.67; 12.65; 13.79; 13.92; 14.25; 14.67; 15.18; 16.21; 16.43; 18.44; 18.82; 20.42; 20.76; 21.09; 21.45; 21.71; 22.47; 22.92; 23.30; 23.89; 24.25; 26.02; 26.54.
  • the hemiheptahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide is characterized by the powder X-ray diffraction diagram below, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees ⁇ 0.2°) and interplanar spacing D (expressed in ⁇ ):
  • the invention also extends to the method for preparing salts of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide in a well-defined crystalline form, characterized in that the 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide is crystallised in a polar medium in the presence of naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, oxalic acid or benzenesulfonic acid.
  • the polar medium preferably consists of one or more solvents chosen from among water, alcohols, ketones, nitriles and esters.
  • the preferred alcohols are ethanol and isopropanol.
  • acetone and methylethylketone are the preferred ketones
  • ethyl acetate is the preferred ester
  • acetonitrile is the preferred nitrile.
  • the polar medium is a binary mixture, one of the components of which is water. Even more preferably, the polar medium is a binary mixture selected from among: acetone/water, ethanol/water, isopropanol/water and methylethylketone/water.
  • the invention also extends to another method for preparation of the crystalline forms of the salts of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide according to the invention, in which the crystallization of the 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide (free base) is initiated by seeding of a very small quantity of crystalline forms of the salts of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide according to the invention, this reaction being carried out in a polar medium and in the presence of the corresponding acid.
  • Obtaining crystalline forms of the novel salts of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide according to the invention has the advantage of enabling the preparation of pharmaceutical formulations which have a constant and reproducible composition and exhibit good characteristics of dissolution and of stability, which is particularly advantageous when the formulations are intended for oral administration.
  • acetone and methylethylketone for ketones and ethyl acetate for esters.
  • Water is a particularly preferred solvent.
  • the polar medium is a binary mixture of which one of the components is water. Even more preferably, the polar medium is a hydro-alcoholic mixture.
  • the polar medium is a binary mixture selected from among: acetone/water, ethanol/water, isopropanol/water and methylethylketone/water.
  • the invention likewise extends to another process for preparation of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide in two well defined hydrated crystalline forms, wherein the crystallization of the 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide (free base) is initiated by seeding of a very small quantity of the hydrated crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide according to the invention, this reaction being carried out in a polar medium and in the presence of sulfuric acid.
  • the crystalline forms (including the hydrated crystalline forms) of the novel salts of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide according to the invention are intended for the treatment of cancer and, more particularly, for the treatment of a carcinoma, a tumor, a neoplasm, a lymphoma, a melanoma, a glioma, a sarcoma or a blastoma.
  • the invention also extends to pharmaceutical compositions including as active principle a salt of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide according to the formula (I) and, even more particularly, the crystalline forms (including the hydrated crystalline forms) of salts of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide according to the invention, with one or more appropriate non-toxic inert carriers.
  • compositions according to the invention mention may be made more particularly of those which are suitable for oral, parenteral (intravenous or subcutaneous) or nasal administration, plain or coated tablets, granules, sublingual tablets, capsules, pills, suppositories, creams, ointments, dermal gels, injectable preparations, drinkable suspensions and chewing gums.
  • Orally administered pharmaceutical compositions are preferred.
  • the useful dosage varies according to the sex, age and weight of the patient, the administration route, the nature of the cancer and any associated treatments, and the useful dosage ranges between 20 mg and 480 mg of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide expressed in free base per day.
  • the white powder was then resuspended with 25 mL of n-heptane and the reaction mixture was subjected to sustained magnetic stirring at 60° C. for 1 hour. Next the reaction mixture was cooled under sustained magnetic stirring to 10° C. at a speed between 1 and 1.5° C./min, then maintained for approximately 1 day at 10° C. After filtration on a porosity 3 glass frit, the solid was dried in a desiccator in vacuo (100 mbar) in order to give the compound of the title with an output of 96%. The solid was characterized by the powder X-ray diffraction diagram and the NMR spectrum detailed in the following Examples 7 and 9.
  • the recording of the data was performed on a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector under the following conditions:
  • the powder X-ray diffraction diagram of the crystalline form of the naphthalene-1,5-disulfonate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide produced using the method according to Example 1 is expressed in terms of line position (Bragg angle 2 theta, expressed in degrees ⁇ 0.2°) and of interplanar spacing d (expressed in ⁇ ).
  • the significant lines are set out in the following table:
  • the powder X-ray diffraction diagram of the crystalline form of the naphthalene-2-sulfonate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide produced using the method according to Example 2 is expressed in terms of line position (Bragg angle 2 theta, expressed in degrees ⁇ 0.2°) and of interplanar spacing d (expressed in ⁇ ).
  • the significant lines are set out in the following table:
  • the powder X-ray diffraction diagram of the crystalline form of the oxalate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide produced using the method according to Example 3 is expressed in terms of line position (Bragg angle 2 theta, expressed in degrees ⁇ 0.2°) and of interplanar spacing d (expressed in ⁇ ).
  • the significant lines are set out in the following table:
  • the powder X-ray diffraction diagram of the crystalline form of the benzenesulfonate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide produced using the method according to Example 4 is expressed in terms of line position (Bragg angle 2 theta, expressed in degrees ⁇ 0.2°) and of interplanar spacing d (expressed in ⁇ ).
  • the significant lines are set out in the following table:
  • the powder X-ray diffraction diagram of the hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide produced using the method according to Example 5 is expressed in terms of line position (Bragg angle 2 theta, expressed in degrees ⁇ 0.2°) and of interplanar spacing d (expressed in ⁇ ).
  • the significant lines are set out in the following table:
  • the powder X-ray diffraction diagram of the hemiheptahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide produced using the method according to Example 6 is expressed in terms of line position (Bragg angle 2 theta, expressed in degrees ⁇ 0.2°) and of interplanar spacing d (expressed in ⁇ ).
  • the significant lines are set out in the following table:
  • the crystalline structure was determined on the powders obtained in the preceding examples using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector. The following parameters were established:
  • ⁇ corresponds to the chemical shift difference between the indexed peak and the peak with the lowest referenced chemical shift.
  • the hygroscopicity of the crystalline forms of the salts of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide according to the invention was evaluated by dynamic vapor sorption (DVS) using a DVS Intrinsic apparatus. A sample of 5 to 10 mg of the substance, weighed accurately, was disposed in a DVS sample pan operating at 25° C. under controlled humidity.
  • the mass variation was recorded on the basis of a balancing bearing at 50% relative humidity, followed by three subsequent linear phases of increasing (from 50 to 90%), of decreasing (from 90 to 0%) and of increasing (from 0 to 50%) the relative humidity at a speed of 10% per hour.
  • the relative humidity was maintained constant when it reached either 0, or 50, or 90% relative humidity, until the mass variation was less than 0.002% per minute, with a time limit of 15 hours.
  • a mass variation of less than 0.2 % was detected by DVS analysis after exposure of a sample to between 0 and 90% relative humidity at 25° C. for the crystalline form of the oxalate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide produced using the method according to Example 3.
  • the hygroscopicity of the hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide according to the invention was evaluated by dynamic vapor sorption (DVS) using a DVS Intrinsic apparatus. A sample of 5 to 10 mg of the substance, weighed accurately, was disposed in a DVS sample pan operating at 25° C. under controlled humidity.
  • the mass variation was recorded on the basis of a balancing bearing at 50% relative humidity, followed by three subsequent linear phases of increasing (from 50 to 90%), of decreasing (from 90 to 0%) and of increasing (from 0 to 50%) the relative humidity at a speed of 10% per hour.
  • the relative humidity was maintained constant when it reached either 0, or 50, or 90 % relative humidity, until the mass variation is less than 0.002% per minute, with a time limit of 15 hours.
  • the hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N- ⁇ 2-[4-(hydroxycarbamoyl)phenoxy]ethyl ⁇ -1-benzofuran-2-carboxamide produced using the method according to Example 5 was stable between 15% relative humidity and 70% relative humidity. Beyond 70% relative humidity, the hemipentahydrate hydrogen sulfate was converted into hemiheptahydrate hydrogen sulfate which was stable between 90% relative humidity and 20% relative humidity. Below 20% relative humidity and to 0% relative humidity, the hemiheptahydrate hydrogen sulfate dehydrated completely and retransferred into hemipentahydrate hydrogen sulfate from 15% relative humidity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • Geophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Remote Sensing (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Environmental & Geological Engineering (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Described herein are salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide, in particular that of formula (I):
Figure US20170266151A1-20170921-C00001
wherein HA is naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, oxalic acid, benzenesulfonic acid, or sulfuric acid, or hydrates thereof, and crystalline forms thereof characterized by the powder X-ray diffraction diagram and the 13C CP/MAS NMR solid state spectrum. Also described are compositions, methods of use and preparation thereof.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of French Patent Application Nos. 1458215 and 1458224, both filed Sep. 3, 2014, which are incorporated herein by reference in their entirety.
    • FIELD OF THE INVENTION
  • The present invention relates to novel salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide or hydrates or polymorphs thereof, methods for preparing the same as well as pharmaceutical compositions and uses thereof.
    • BACKGROUND OF THE INVENTION
  • 3-[(Dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide, also referred to as abexinostat, is a histone deacetylase (HDAC) inhibitor which is described in the patent application WO 2004/092116. It was shown to inhibit cell growth and induce apoptosis in tumor cells cultured in vitro, and inhibit tumor growth in viva in xenograft models (Buggy et al., Mol. Cancer Ther. 2006, 5 (5), 1309). Given its pharmacological profile, abexinostat is intended to be used in the treatment of cancer.
    • SUMMARY OF THE INVENTION
  • The present invention relates to novel salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide or hydrates or crystalline forms thereof, methods for preparing or using the same as well as pharmaceutical compositions containing the same.
  • More particularly, the invention relates to salts of 3-[(dimethylamino) methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide of formula (I):
  • Figure US20170266151A1-20170921-C00002
  • in which HA is naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, oxalic acid, benzenesulfonic acid, or sulfuric acid or hydrates thereof.
  • The present invention also relates to novel crystalline forms of the salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide of formula (I), methods for preparing the same as well as pharmaceutical compositions containing the same, and uses thereof.
  • These and other aspects and embodiments are described in following detailed description.
    • DETAILED DESCRIPTION OF THE INVENTION
  • It should be understood that the detailed description and the specific examples, while indicating specific embodiments, are given by way of illustration only, since various changes and modifications within the spirit and scope of the present disclosure will become apparent to those skilled in the art from this detailed description. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in the application including, but not limited to, patents, patent applications, articles, books, manuals, and treatises are hereby expressly incorporated by reference in their entirety for any purpose.
  • The patent application WO 2004/092115 describes two different access routes for producing 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide. In both cases, 3-methylbenzofuran-2-carboxylic acid is used as the starting material, but the functionalization of this central ring by the dimethylamino group in position 3 is carried out at different stages of the synthesis processes, before or after the coupling of the derivative of benzofuran-2-carboxylic acid with methyl 4-(2-aminoethoxy)benzoate. The application WO 2004/092115 specifically describes the production of the hydrochloride of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide. However, the use of this salt on an industrial scale is difficult because of its hygroscopic properties.
  • From an industrial point of view, it is important to be able to synthesize the compound with excellent purity, and in particular in a highly reproducible form, exhibiting valuable properties of dissolution, filtration, drying, ease of formulation and stability enabling the prolonged storage thereof without specific temperature, light, humidity or oxygen level conditions.
  • In one aspect, the present invention relates to naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid oxalic acid, benzenesulfonic acid, or sulfuric acid salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide or one of the hydrates thereof, a method for preparing the same as well as pharmaceutical compositions containing the same, and uses thereof.
  • In one aspect, the invention relates to salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide of formula (Ia):
  • Figure US20170266151A1-20170921-C00003
  • in which HA is naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, oxalic acid or benzenesulfonic acid.
  • In another aspect, the subject matter of the invention relates to the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide of formula (Ib):
  • Figure US20170266151A1-20170921-C00004
  • wherein HA is sulfuric acid, as well as hydrates thereof.
  • The present invention also describes methods for producing salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide in well-defined and reproducible crystalline forms or hydrated crystalline forms, inhibiting very good stability compatible with the industrial constraints on preparation (in particular, drying) and storage of pharmaceutical compositions.
  • In one aspect, provided is a crystalline form of the naphthalene-1,5-disulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to the invention, which is characterized by a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2°): 6.87; 10.71; 11.31; 13.97; 18.51; 21.49; 21.84; 24.56. More particularly, the crystalline form of the naphthalene-1,5-disulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide carboxamide is characterized by the following diffraction lines: 6.87; 10.71; 11.31; 13.97; 18.51; 20.71; 21.18; 21.49; 21.84; 22.74; 24.56.
  • More specifically, the crystalline form of the naphthalene-1,5-disulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide is characterized by the powder X-ray diffraction diagram below, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and interplanar spacing d (expressed in Å):
  • Line no. Angle 2 theta (degrees) Interplanar spacing (Å)
    1 6.87 12.861
    2 10.71 8.262
    3 11.31 7.821
    4 13.97 6.341
    5 18.51 4.794
    6 20.71 4.288
    7 21.18 4.194
    8 21.49 4.134
    9 21.84 4.069
    10 22.74 3.910
    11 24.56 3.625
  • Finally, the crystalline form of the naphthalene-1,5-disulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide has also been characterized by solid state NMR spectroscopy and the 13C CP/MAS (cross polarization/magic angle spinning) spectrum exhibits the following peaks (expressed in ppm±0.2 ppm):
  • Peak no. Chemical shift (ppm) Δδ ppm (/37.8 ppm)
    1 167.9 130.1
    2 161.1 123.3
    3 158.6 120.8
    4 153.8 116.0
    5 145.5 107.7
    6 142.4 104.6
    7 130.3 92.5
    8 126.0 88.2
    9 122.4 84.6
    10 119.6 81.8
    11 114.3 76.5
    12 64.5 26.7
    13 51.2 13.4
    14 45.6 7.8
    15 44.0 6.2
    16 37.8 0.0
  • In one aspect, provided is a crystalline form of the naphthalene-2-sulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to the invention, which is characterized by a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed m degrees±0.2): 8.92; 9.33; 10.85; 17.89; 19.79; 21.79; 26.39.
  • More particularly, the crystalline form of the naphthalene-2-sulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide is characterized by the following diffraction lines: 8.92; 9.33; 10.85; 11.78; 17.89; 19.79; 19.99; 21.79; 25.23; 26.39.
  • More specifically, the crystalline form of the naphthalene-2-sulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide is characterized by the powder X-ray diffraction diagram below, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2) and interplanar spacing d (expressed in Å):
  • Line no. Angle 2 theta (degrees) Interplanar spacing (Å)
    1 8.92 9.917
    2 9.33 9.476
    3 10.85 8.153
    4 11.78 7.515
    5 17.89 4.957
    6 19.79 4.484
    7 19.99 4.440
    8 21.79 4.078
    9 25.23 3.529
    10 26.39 3.376
  • Finally, the crystalline form of the naphthalene-2-sulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide has also been characterized by solid state NMR spectroscopy and the 13C CP/MAS spectrum exhibits the following peaks (expressed in ppm±0.2 ppm):
  • Peak no. Chemical shift (ppm) Δδ ppm (/41.7 ppm)
    1 165.7 124.0
    2 154.2 112.5
    3 141.1 99.4
    4 139.5 97.8
    5 133.2 91.5
    6 128.5 86.8
    7 127.6 85.9
    8 126.0 84.3
    9 124.6 82.9
    10 122.4 80.7
    11 113.1 71.4
    12 64.8 23.1
    13 63.2 21.5
    14 50.7 9.0
    15 47.2 5.5
    16 45.5 3.8
    17 42.8 1.1
    18 41.7 0.0
  • In one aspect, provided is a crystalline form of the oxalate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to the invention, which is characterized by a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2): 9.11; 9.67; 16.39; 17.73; 18.49; 18.65; 18.79; 21.96; 22.39; 23.39; 26.76; 27.92; 30.72. More particularly, the crystalline form of the oxalate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide is characterized by the following diffraction lines: 9.11; 9.67; 16.39; 16.56; 17.73; 18.49; 18.65; 18.79; 20.35; 20.85; 21.00; 21.96; 22.39; 23.39; 23.91; 26.22; 26.76; 27.92; 30.72.
  • More specifically, the crystalline form of the oxalate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide is characterized by the powder X-ray diffraction diagram below, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and of interplanar spacing d (expressed in Å):
  • Line no. Angle 2 theta (degrees) Interplanar spacing (Å)
    1 9.11 9.704
    2 9.67 9.142
    3 16.39 5.408
    4 16.56 5.354
    5 17.73 5.004
    6 18.49 4.798
    7 18.65 4.758
    8 18.79 4.721
    9 20.35 4.364
    10 20.85 4.260
    11 21.00 4.229
    12 21.96 4.048
    13 22.39 3.971
    14 23.39 3.804
    15 23.91 3.722
    16 26.22 3.399
    17 26.76 3.332
    18 27.92 3.196
    19 30.72 2.911
  • Finally, the crystalline form of the oxalate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide has also been characterized by solid state NMR spectroscopy and the 13C CP/MAS spectrum exhibits the following peaks (expressed in ppm±0.2 ppm):
  • Peak no. Chemical shift (ppm) Δδ ppm (/42.9 ppm)
    1 168.9 126.0
    2 162.6 119.7
    3 153.7 110.8
    4 146.1 103.2
    5 130.0 87.1
    6 128.7 85.8
    7 127.4 84.5
    8 125.8 82.9
    9 124.3 81.4
    10 123.2 80.3
    11 119.8 76.9
    12 118.5 75.6
    13 114.2 71.3
    14 113.5 70.6
    15 111.8 68.9
    16 65.8 22.9
    17 50.9 8.0
    18 47.3 4.4
    19 42.9 0.0
  • In one aspect provided is a novel crystalline form of the benzenesulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to the Invention, which is characterized by a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2°): 8.08; 10.03; 10.36; 13.63; 15.00; 16.19; 17.73; 17.90; 18.77; 19.77; 21.98; 22.45. More particularly, the crystalline form of the benzenesulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide is characterized by the following diffraction lines: 8.08; 10.03; 10.36; 11.86; 12.66; 13.63; 15.00; 16.19; 16.39; 16.52; 17.73; 17.90; 18.77; 19.77; 20.20; 20.86; 21.11; 21.98; 22.45; 23.84; 26.13; 26.74; 27.44.
  • More specifically, the crystalline form of the benzenesulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide is characterized by the powder X-ray diffraction diagram below, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and of interplanar spacing d (expressed in Å):
  • Line no. Angle 2 theta (degrees) Interplanar spacing (Å)
    1 8.08 10.949
    2 10.03 8.818
    3 10.36 8.539
    4 11.86 7.463
    5 12.66 6.992
    6 13.63 6.498
    7 15.00 5.906
    8 16.19 5.473
    9 16.39 5.407
    10 16.52 5.366
    11 17.73 5.002
    12 17.90 4.954
    13 18.77 4.728
    14 19.77 4.492
    15 20.20 4.395
    16 20.86 4.259
    17 21.11 4.209
    18 21.98 4.043
    19 22.45 3.961
    20 23.84 3.732
    21 26.13 3.411
    22 26.74 3.333
    23 27.44 3.251
  • Finally, the crystalline form of the benzenesulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide has also been characterized by solid state NMR spectroscopy and the 13C CP/MAS spectrum exhibits the following peaks (expressed in ppm±0.2 ppm):
  • Peak no. Chemical shift (ppm) Δδ ppm (/42.0 ppm)
    1 165.5 123.5
    2 161.7 119.7
    3 152.6 110.6
    4 145.9 103.9
    5 128.2 86.2
    6 126.5 84.5
    7 121.6 79.6
    8 114.3 72.3
    9 111.2 69.2
    10 68.4 26.4
    11 51.2 9.2
    12 44.5 2.5
    13 42.0 0.0
  • In another aspect, provided is a crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide or a hydrate thereof. In one embodiment, the hydrate is a hemipentahydrate. In another embodiment, the hydrate is a hemiheptahydrate.
  • In one embodiment, the hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to the invention is characterized by a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2°): 6.92; 9.01; 11.04; 13.87; 14.24; 14.89; 15.06; 17.34; 18.96; 20.05; 21.49; 24.34; 24.59; 25.19; 25.89. More particularly, the hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide is characterized by the following diffraction lines: 6.92; 9.01; 11.04; 11.82; 13.87; 14.24; 14.89; 15.06; 17.34; 18.96; 20.05; 20.84; 21.23; 21.49; 22.68; 22.85; 24.34; 24.59; 25.19; 25.89; 28.28.
  • More specifically, the hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide is characterized by the powder X-ray diffraction diagram below, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and interplanar spacing d (expressed in Å):
  • Line no. Angle 2 theta (degrees) Interplanar spacing (Å)
    1 6.92 12.782
    2 9.01 9.815
    3 11.04 8.015
    4 11.82 7.489
    5 13.87 6.386
    6 14.24 6.222
    7 14.89 5.949
    8 15.06 5.882
    9 17.34 5.114
    10 18.96 4.681
    11 20.05 4.429
    12 20.84 4.262
    13 21.23 4.185
    14 21.49 4.134
    15 22.68 3.920
    16 22.85 3.892
    17 24.34 3.657
    18 24.59 3.620
    19 25.19 3.535
    20 25.89 3.441
    21 28.28 3.156
  • Finally, the hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide has also been characterized by solid state NMR spectroscopy and the 13C CP/MAS (cross polarization/magic angle spinning) spectrum exhibits the following peaks (expressed in ppm±0.2 ppm):
  • Peak no. Chemical shift (ppm) Δδ ppm (/38.4 ppm)
    1 166.0 127.6
    2 159.2 120.8
    3 146.8 108.4
    4 123.1 84.7
    5 121.8 83.4
    6 120.7 82.3
    7 114.8 76.4
    8 112.8 74.4
    9 112.1 73.7
    10 110.0 71.6
    11 107.1 68.7
    12 66.7 28.3
    13 63.0 24.6
    14 49.0 10.6
    15 41.7 3.3
    16 40.2 1.8
    17 38.4 0.0
  • In one embodiment, the hemiheptahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to the invention is characterized by a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2°): 9.99; 10.67; 13.79; 13.92; 14.25; 14.67; 15.18; 16.21; 18.44; 18.82; 20.42; 21.71; 22.47; 23.30; 24.25. More particularly, the hemiheptahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide is characterized by the following diffraction lines: 9.99; 10.67; 12.65; 13.79; 13.92; 14.25; 14.67; 15.18; 16.21; 16.43; 18.44; 18.82; 20.42; 20.76; 21.09; 21.45; 21.71; 22.47; 22.92; 23.30; 23.89; 24.25; 26.02; 26.54.
  • More specifically, the hemiheptahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide is characterized by the powder X-ray diffraction diagram below, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and interplanar spacing D (expressed in Å):
  • Line no. Angle 2 theta (degrees) Interplanar spacing (Å)
    1 9.99 8.838
    2 10.67 8.284
    3 12.65 6.995
    4 13.79 6.418
    5 13.92 6.356
    6 14.25 6.211
    7 14.67 6.032
    8 15.18 5.831
    9 16.21 5.464
    10 16.43 5.389
    11 18.44 4.808
    12 18.82 4.712
    13 20.42 4.345
    14 20.76 4.276
    15 21.09 4.209
    16 21.45 4.140
    17 21.71 4.090
    18 22.47 3.953
    19 22.92 3.877
    20 23.30 3.814
    21 23.89 3.721
    22 24.25 3.667
    23 26.02 3.422
    24 26.54 3.355
  • The invention also extends to the method for preparing salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide in a well-defined crystalline form, characterized in that the 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide is crystallised in a polar medium in the presence of naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, oxalic acid or benzenesulfonic acid. The polar medium preferably consists of one or more solvents chosen from among water, alcohols, ketones, nitriles and esters. As used herein:
      • “alcohols” are understood to mean C1-C6 alcohols such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol, pentanol, 2-pentanol, 3-pentanol, isopentanol, hexanol;
      • “ketones” are understood to mean C3-C6 ketones such as acetone, methylethyl ketone, 2-pentanone, 3-pentanone, 3-methyl-2-butanone, 2-hexanone, 3-hexanone, ethylisopropylketone, methylisopropylketone, 2,2-dimethyl-3-butanone;
      • “nitriles” are understood to mean acetonitrile, acrylonitrile, propanenitrile or benzonitrile;
      • “esters” are understood to mean C3-C8 esters such as ethyl formate, isopropyl formate, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate, tert-butyl acetate, pentyl acetate, isopentyl acetate, hexyl acetate.
  • The preferred alcohols are ethanol and isopropanol. Among the solvents, acetone and methylethylketone are the preferred ketones, ethyl acetate is the preferred ester and acetonitrile is the preferred nitrile.
  • Alternatively, the polar medium is a binary mixture, one of the components of which is water. Even more preferably, the polar medium is a binary mixture selected from among: acetone/water, ethanol/water, isopropanol/water and methylethylketone/water.
  • In the crystallization method according to the invention, if is possible to use 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (free base) obtained by any method.
  • The invention also extends to another method for preparation of the crystalline forms of the salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to the invention, in which the crystallization of the 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (free base) is initiated by seeding of a very small quantity of crystalline forms of the salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to the invention, this reaction being carried out in a polar medium and in the presence of the corresponding acid. In this second crystallization method according to the invention, it is also possible to use 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (free base) obtained by any method.
  • Obtaining crystalline forms of the novel salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to the invention has the advantage of enabling the preparation of pharmaceutical formulations which have a constant and reproducible composition and exhibit good characteristics of dissolution and of stability, which is particularly advantageous when the formulations are intended for oral administration. More precisely, the use of crystalline forms of the novel salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to the invention is particularly advantageous on an industrial scale taking account of their low hydroscopicity.
  • Among the preferred solvents, use will be made of acetone and methylethylketone for ketones and ethyl acetate for esters. Water is a particularly preferred solvent.
  • Alternatively, the polar medium is a binary mixture of which one of the components is water. Even more preferably, the polar medium is a hydro-alcoholic mixture. Advantageously, the polar medium is a binary mixture selected from among: acetone/water, ethanol/water, isopropanol/water and methylethylketone/water.
  • In the crystallization process according to the invention, it is possible to use 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (free base) obtained by any method.
  • The invention likewise extends to another process for preparation of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide in two well defined hydrated crystalline forms, wherein the crystallization of the 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (free base) is initiated by seeding of a very small quantity of the hydrated crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to the invention, this reaction being carried out in a polar medium and in the presence of sulfuric acid. In this second crystallization process according to the invention, it is also possible to use 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (free base) obtained by any method.
  • Obtaining hydrated crystalline forms of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to the invention has the advantage of being easily manipulated and enabling the preparation of pharmaceutical formulations which have a constant and reproducible composition whilst exhibiting good characteristics of dissolution and of stability, which is particularly advantageous when the formulations are intended for oral administration. More precisely, the use of hydrated crystalline forms of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to the invention is particularly advantageous on an industrial scale.
  • The crystalline forms (including the hydrated crystalline forms) of the novel salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to the invention are intended for the treatment of cancer and, more particularly, for the treatment of a carcinoma, a tumor, a neoplasm, a lymphoma, a melanoma, a glioma, a sarcoma or a blastoma.
  • The invention also extends to pharmaceutical compositions including as active principle a salt of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to the formula (I) and, even more particularly, the crystalline forms (including the hydrated crystalline forms) of salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to the invention, with one or more appropriate non-toxic inert carriers. Among the pharmaceutical compositions according to the invention, mention may be made more particularly of those which are suitable for oral, parenteral (intravenous or subcutaneous) or nasal administration, plain or coated tablets, granules, sublingual tablets, capsules, pills, suppositories, creams, ointments, dermal gels, injectable preparations, drinkable suspensions and chewing gums.
  • Orally administered pharmaceutical compositions are preferred.
  • The useful dosage varies according to the sex, age and weight of the patient, the administration route, the nature of the cancer and any associated treatments, and the useful dosage ranges between 20 mg and 480 mg of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide expressed in free base per day.
  • The examples below illustrate the invention but do not limit it in any way.
    • EXAMPLE 1 Method for Producing the Crystalline Form of the naphthalene-1,5-disulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
  • In a 50 mL flask, an equivalent of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (free base) (1245.0 mg; 3.133 mmol) was added, followed by a half-equivalent of naphthalene-1,5-disulfonic acid tetrahydrate (564.5 mg; 1.566 mmol). Then 25 mL of isopropanol were added and the reaction mixture was subjected to sustained magnetic stirring at 60° C. for 1 hour. Next the reaction mixture was cooled under sustained magnetic stirring to 10° C. at a speed between 1 and 1.5° C./min, then maintained for approximately 1 day at 10° C. After filtration on a porosity 3 glass frit, the solid was dried in a desiccator in vacuo (100 mbar) in order to give the compound of the title with an output of 96%. The solid was characterized by the powder X-ray diffraction diagram and the NMR spectrum detailed in the following Examples 7 and 9.
    • EXAMPLE Method for Producing the Crystalline Form of the naphthalene-2-sulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
  • In a 50 mL flask, an equivalent of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (free base) (1115.5 mg; 2.807 mmol) was added, followed by an equivalent of naphthalene-2-sulfonic acid monohydrate (635.9 mg; 2.806 mmol). Then 25 mL of acetonitrile were added and the reaction mixture was subjected to sustained magnetic stirring at 60° C. for 1 hour. Next the reaction mixture was cooled under sustained magnetic stirring to 10° C. at a speed between 1 and 1.5° C./min, then maintained for approximately 1 day at 10° C. After filtration on a porosity 3 glass frit, the solid was dried in a desiccator in vacuo (100 mbar) in order to give the compound of the title with an output of 96 %. The solid was characterized by the powder X-ray diffraction diagram and the NMR spectrum detailed in the following Examples 7 and 9.
    • EXAMPLE 3 Method for Producing the Crystalline Form of the Oxalate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
  • In a 50 mL flask, an equivalent of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (free base) (1382.8 mg; 3.479 mmol) was added, followed by an equivalent of oxalic acid. (313.1 mg; 3.477 mmol). Then 25 mL of ethanol were added and the reaction mixture was subjected to sustained magnetic stirring at 60° C. for 1 hour. Next the reaction mixture was cooled under sustained magnetic stirring to 10° C. at a speed between 1 and 1.5° C./min, then maintained for approximately 1 day at 10° C. After filtration on a porosity 3 glass frit, the solid was dried in a desiccator in vacuo (100 mbar) in order to give the compound of the title with an output of 95%. The solid was characterized by the powder X-ray diffraction diagram and the NMR spectrum detailed in the following Examples 7 and 9.
    • EXAMPLE 4 Method for Producing the Crystalline Form of the Benzenesulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
  • In a 100 mL flask, an equivalent of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (free base) (1496 mg; 3.746 mmol) was added, followed by 35 mL of isopropanol and 5 mL of water. The mixture was brought to reflux. Then an equivalent of benzenesulfonic acid (599 mg; 3.787 mmol) were added and the reaction mixture was held at reflux under sustained magnetic stirring for 1 hour. Next the reaction mixture was cooled under sustained magnetic stirring to ambient temperature then maintained for approximately 1 hour at ambient temperature. After filtration on a disposable Chemrus 10 μm frit and rinsing with 2×1 mL of isopropanol, the solid was dried in an oven at 40° C. in vacuo (10 mbar) for 24 hours in order to gives the compound of the title with a yield of 83%. The solid was characterized by the powder X-ray diffraction diagram and the NMR spectrum detailed in the following Examples 7 and 9.
    • EXAMPLE 5 Method for Producing the Hemipentahydrate Crystalline Form of the Hydrogen Sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
  • In a 50 mL flask, an equivalent of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (free base) (1512.8 mg; 3.807 mmol) was added, followed by a half-equivalent of sulfuric acid (5.302 mL of an aqueous solution of 0.359 mol·L−1; 1.903 mmol). the mixture was subjected to a magnetic stirring until a clear solution is obtained. The water was then evaporated under a stream of air. The white powder was then resuspended with 25 mL of n-heptane and the reaction mixture was subjected to sustained magnetic stirring at 60° C. for 1 hour. Next the reaction mixture was cooled under sustained magnetic stirring to 10° C. at a speed between 1 and 1.5° C./min, then maintained for approximately 1 day at 10° C. After filtration on a porosity 3 glass frit, the solid was dried in a desiccator in vacuo (100 mbar) in order to give the compound of the title with an output of 96%. The solid was characterized by the powder X-ray diffraction diagram and the NMR spectrum detailed in the following Examples 7 and 9.
    • EXAMPLE 6 Method for Producing the Hemiheptahydrate Crystalline Form of the Hydrogen Sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
  • A vial containing 100 mg of hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide, hemipentahydrate placed for 3 days in a bell jar containing a saturated saline solution of KNO3 (90% relative humidity) at ambient temperature led to the formation of the compound of the title with a quantitative yield. The resulting solid was characterized by the powder X-ray diffraction diagram detailed in the following Example 7.
    • EXAMPLE 7 Powder X-ray Diffraction Diagrams of the Crystalline Forms of the Salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide According to the Invention
  • The recording of the data was performed on a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector under the following conditions:
    • Voltage 45 kV, current 40 mA;
    • Mounting theta/theta;
    • Anode copper;
    • K alpha-1 wavelength: 1.54060 Å;
    • K alpha-2 wavelength: 1.54443 Å;
    • K alpha-2/K alpha-1 ratio: 0.5;
    • Measurement mode: continuous from 3° to 55° (Bragg angle 2 theta) with incrementation by 0.017°;
    • Acquisition time: 15 min.
  • Crystalline form of the naphthalene-1,5-disulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
  • The powder X-ray diffraction diagram of the crystalline form of the naphthalene-1,5-disulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 1 is expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and of interplanar spacing d (expressed in Å). The significant lines are set out in the following table:
  • Line no. Angle 2 theta (degrees) Interplanar spacing (Å)
    1 6.87 12.861
    2 10.71 8.262
    3 11.31 7.821
    4 13.97 6.341
    5 18.51 4.794
    6 20.71 4.288
    7 21.18 4.194
    8 21.49 4.134
    9 21.84 4.069
    10 22.74 3.910
    11 24.56 3.625
  • Crystalline form of the naphthalene-2-sulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
  • The powder X-ray diffraction diagram of the crystalline form of the naphthalene-2-sulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 2 is expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and of interplanar spacing d (expressed in Å). The significant lines are set out in the following table:
  • Line no. Angle 2 theta (degrees) Interplanar spacing (Å)
    1 8.92 9.917
    2 9.33 9.476
    3 10.85 8.153
    4 11.78 7.515
    5 17.89 4.957
    6 19.79 4.484
    7 19.99 4.440
    8 21.79 4.078
    9 25.23 3.529
    10 26.39 3.376
  • Crystalline form of the oxalate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
  • The powder X-ray diffraction diagram of the crystalline form of the oxalate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 3 is expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and of interplanar spacing d (expressed in Å). The significant lines are set out in the following table:
  • Line no. Angle 2 theta (degrees) Interplanar spacing (Å)
    1 9.11 9.704
    2 9.67 9.142
    3 16.39 5.408
    4 16.56 5.354
    5 17.73 5.004
    6 18.49 4.798
    7 18.65 4.758
    8 18.79 4.721
    9 20.35 4.364
    10 20.85 4.260
    11 21.00 4.229
    12 21.96 4.048
    13 22.39 3.971
    14 23.39 3.804
    15 23.91 3.722
    16 26.22 3.399
    17 26.76 3.332
    18 27.92 3.196
    19 30.72 2.911
  • Crystalline form of the benzenesulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
  • The powder X-ray diffraction diagram of the crystalline form of the benzenesulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 4 is expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and of interplanar spacing d (expressed in Å). The significant lines are set out in the following table:
  • Line no. Angle 2 theta (degrees) Interplanar spacing (Å)
    1 8.08 10.949
    2 10.03 8.818
    3 10.36 8.539
    4 11.86 7.463
    5 12.66 6.992
    6 13.63 6.498
    7 15.00 5.906
    8 16.19 5.473
    9 16.39 5.407
    10 16.52 5.366
    11 17.73 5.002
    12 17.90 4.954
    13 18.77 4.728
    14 19.77 4.492
    15 20.20 4.395
    16 20.86 4.259
    17 21.11 4.209
    18 21.98 4.043
    19 22.45 3.961
    20 23.84 3.732
    21 26.13 3.411
    22 26.74 3.333
    23 27.44 3.251
  • Hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide:
  • The powder X-ray diffraction diagram of the hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 5 is expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and of interplanar spacing d (expressed in Å). The significant lines are set out in the following table:
  • Line no. Angle 2 theta (degrees) Interplanar spacing (Å)
    1 6.92 12.782
    2 9.01 9.815
    3 11.04 8.015
    4 11.82 7.489
    5 13.87 6.386
    6 14.24 6.222
    7 14.89 5.949
    8 15.06 5.882
    9 17.34 5.114
    10 18.96 4.681
    11 20.05 4.429
    12 20.84 4.262
    13 21.23 4.185
    14 21.49 4.134
    15 22.68 3.920
    16 22.85 3.892
    17 24.34 3.657
    18 24.59 3.620
    19 25.19 3.535
    20 25.89 3.441
    21 28.28 3.156
  • Hemiheptahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide:
  • The powder X-ray diffraction diagram of the hemiheptahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 6 is expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and of interplanar spacing d (expressed in Å). The significant lines are set out in the following table:
  • Line no. Angle 2 theta (degrees) Interplanar spacing (Å)
    1 9.99 8.838
    2 10.67 8.284
    3 12.65 6.995
    4 13.79 6.418
    5 13.92 6.356
    6 14.25 6.211
    7 14.67 6.032
    8 15.18 5.831
    9 16.21 5.464
    10 16.43 5.389
    11 18.44 4.808
    12 18.82 4.712
    13 20.42 4.345
    14 20.76 4.276
    15 21.09 4.209
    16 21.45 4.140
    17 21.71 4.090
    18 22.47 3.953
    19 22.92 3.877
    20 23.30 3.814
    21 23.89 3.721
    22 24.25 3.667
    23 26.02 3.422
    24 26.54 3.355
    • EXAMPLE 8 Determination of the Lattices of the Crystalline Forms of the Salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
  • The crystalline structure was determined on the powders obtained in the preceding examples using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector. The following parameters were established:
  • Salts Lattice parameters Space group
    Naphthalene-1,5-disulfonate a = 10.586 Å P -1
    (produced using the method b = 13.897 Å
    according to Example 1) c = 9.879 Å
    α = 93.150°
    β = 102.358°
    γ = 110.806°
    Oxalate a = 5.594 Å P 1 2l/c 1
    (produced using the method b = 20.711 Å
    according to Example 3) c = 20.285 Å
    β = 107.081
    Benzenesulfonate a = 10.816 Å P 1 2l/c 1
    (produced using the method b = 13.965 Å
    according to Example 4) c = 19.784 Å
    β = 117.490°
    Hydrogen sulfate, hemipentahydrate a = 13.123 Å P -1
    (produced using the method b = 14.696 Å
    according to Example 5) c = 12.967 Å
    α = 99.965°
    β = 103.304°
    γ = 90.348°
    • EXAMPLE 9 Solid State NMR Spectrum of the Crystalline Forms oft he Salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
  • The 13C NMR spectra were recorded at ambient temperature using a Bruker SB Avance III HD 400 spectrometer with a probe of the 4 mm CP/MAS SB VTN type under the following conditions:
    • Frequency: 100.65 MHz;
    • Spectral width: 40 kHz;
    • Magic angle spinning rate of sample: 10 kHz;
    • Pulse sequence: CP (Cross Polarization) with SPINAL64 decoupling;
    • Repetition delay: 10s;
    • Acquisition time: 46 ms;
    • Contact time: 4 ms;
    • Number of scans: 4096.
  • An apodization function (“10 Hz line broadening”) was applied before the Fourier transform. The spectra thus obtained were referenced relative to a sample of adamantane as external sample (the highest-frequency peak of adamantane has a chemical shift of 38.5 ppm). The peaks observed are expressed in ppm±0.2 ppm.
  • Δδ ppm: Δδ corresponds to the chemical shift difference between the indexed peak and the peak with the lowest referenced chemical shift.
  • Crystalline form of the naphthalene-1,5-disulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
  • The crystalline form of the naphthalene-1,5-disulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 1 exhibits the following peaks:
  • Peak no. Chemical shift (ppm) Δδ ppm (/37.8 ppm)
    1 167.9 130.1
    2 161.1 123.3
    3 158.6 120.8
    4 153.8 116.0
    5 145.5 107.7
    6 142.4 104.6
    7 130.3 92.5
    8 126.0 88.2
    9 122.4 84.6
    10 119.6 81.8
    11 114.3 76.5
    12 64.5 26.7
    13 51.2 13.4
    14 45.6 7.8
    15 44.0 6.2
    16 37.8 0.0
  • Crystalline form of the naphthalene-2-sulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
  • The crystalline form of the naphthalene-2-sulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 2 exhibits the following peaks:
  • Peak no. Chemical shift (ppm) Δδ ppm (/41.7 ppm)
    1 165.7 124.0
    2 154.2 112.5
    3 141.1 99.4
    4 139.5 97.8
    5 133.2 91.5
    6 128.5 86.8
    7 127.6 85.9
    8 126.0 84.3
    9 124.6 82.9
    10 122.4 80.7
    11 113.1 71.4
    12 64.8 23.1
    13 63.2 21.5
    14 50.7 9.0
    15 47.2 5.5
    16 45.5 3.8
    17 42.8 1.1
    18 41.7 0.0
  • Crystalline form of the oxalate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
  • The crystalline form of the oxalate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 3 exhibits the following peaks:
  • Peak no. Chemical shift (ppm) Δδ ppm (/42.9 ppm)
    1 168.9 126.0
    2 162.6 119.7
    3 153.7 110.8
    4 146.1 103.2
    5 130.0 87.1
    6 128.7 85.8
    7 127.4 84.5
    8 125.8 82.9
    9 124.3 81.4
    10 123.2 80.3
    11 119.8 76.9
    12 118.5 75.6
    13 114.2 71.3
    14 113.5 70.6
    15 111.8 68.9
    16 65.8 22.9
    17 50.9 8.0
    18 47.3 4.4
    19 42.9 0.0
  • Crystalline form of the benzenesulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
  • The crystalline form of the benzenesulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 4 exhibits the following peaks:
  • Peak no. Chemical shift (ppm) Δδ ppm (/42.0 ppm)
    1 165.5 123.5
    2 161.7 119.7
    3 152.6 110.6
    4 145.9 103.9
    5 128.2 86.2
    6 126.5 84.5
    7 121.6 79.6
    8 114.3 72.3
    9 111.2 69.2
    10 68.4 26.4
    11 51.2 9.2
    12 44.5 2.5
    13 42.0 0.0
  • The hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 5 exhibits the following peaks:
  • Peak no. Chemical shift (ppm) Δδ ppm (/38.4 ppm)
    1 166.0 127.6
    2 159.2 120.8
    3 146.8 108.4
    4 123.1 84.7
    5 121.8 83.4
    6 120.7 82.3
    7 114.8 76.4
    8 112.8 74.4
    9 112.1 73.7
    10 110.0 71.6
    11 107.1 68.7
    12 66.7 28.3
    13 63.0 24.6
    14 49.0 10.6
    15 41.7 3.3
    16 40.2 1.8
    17 38.4 0.0
    • EXAMPLE 10 Hygroscopy
  • The hygroscopicity of the crystalline forms of the salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to the invention was evaluated by dynamic vapor sorption (DVS) using a DVS Intrinsic apparatus. A sample of 5 to 10 mg of the substance, weighed accurately, was disposed in a DVS sample pan operating at 25° C. under controlled humidity. The mass variation was recorded on the basis of a balancing bearing at 50% relative humidity, followed by three subsequent linear phases of increasing (from 50 to 90%), of decreasing (from 90 to 0%) and of increasing (from 0 to 50%) the relative humidity at a speed of 10% per hour. The relative humidity was maintained constant when it reached either 0, or 50, or 90% relative humidity, until the mass variation was less than 0.002% per minute, with a time limit of 15 hours.
  • A mass variation of less than 1% was detected by DVS analysis after exposure of a sample to between 0 and 90% relative humidity at 25° C. for the crystalline form of the naphthalene-1,5-disulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 1; the crystalline form of the naphthalene-2-sulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 2; and the crystalline form of the benzenesulfonate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 4.
  • A mass variation of less than 0.2 % was detected by DVS analysis after exposure of a sample to between 0 and 90% relative humidity at 25° C. for the crystalline form of the oxalate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 3.
  • Consequently, the crystalline forms of the salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the methods of Examples 1 to 4 have a low hygroscopicity enabling a particularly advantageous use thereof on an industrial scale in the preparation of pharmaceutical formulations.
  • The hygroscopicity of the hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to the invention was evaluated by dynamic vapor sorption (DVS) using a DVS Intrinsic apparatus. A sample of 5 to 10 mg of the substance, weighed accurately, was disposed in a DVS sample pan operating at 25° C. under controlled humidity. The mass variation was recorded on the basis of a balancing bearing at 50% relative humidity, followed by three subsequent linear phases of increasing (from 50 to 90%), of decreasing (from 90 to 0%) and of increasing (from 0 to 50%) the relative humidity at a speed of 10% per hour. The relative humidity was maintained constant when it reached either 0, or 50, or 90 % relative humidity, until the mass variation is less than 0.002% per minute, with a time limit of 15 hours.
  • The hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 5 was stable between 15% relative humidity and 70% relative humidity. Beyond 70% relative humidity, the hemipentahydrate hydrogen sulfate was converted into hemiheptahydrate hydrogen sulfate which was stable between 90% relative humidity and 20% relative humidity. Below 20% relative humidity and to 0% relative humidity, the hemiheptahydrate hydrogen sulfate dehydrated completely and retransferred into hemipentahydrate hydrogen sulfate from 15% relative humidity.
  • Consequently the hemipentahydrate crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide produced using the method according to Example 5 has properties which enable it to be easily manipulated—in particular during the preparation of pharmaceutical formulations—over wide ranges of relative humidity values.
    • EXAMPLE 11 Pharmaceutical Compositions
  • Formula for preparation of 1000 tablets each containing a dose of 100 mg of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (expressed as equivalent to the base):
  •
    Naphthalene-2-sulfonate of 3-[(dimethylamino)methyl]-N- 157.1 g
    {2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-
    2-carboxamide
    Lactose monohydrate 216.1 g
    Magnesium stearate 2.5 g
    Corn starch 75 g
    Maltodextrin 50 g
    Anhydrous colloidal silica 1 g
    Sodium carboxymethylcellulose 15 g
  • Formula for preparation of 1000 tablets each containing a dose of 100 mg of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (expressed as equivalent to the base):
  •
    Benzenesulfonate of 3-[(dimethylamino)methyl]-N-{2- 139.8 g
    [4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-
    2-carboxamide
    Lactose monohydrate 207.8 g
    Magnesium stearate 2.5 g
    Corn starch 75 g
    Maltodextrin 50 g
    Anhydrous colloidal silica 1 g
    Sodium carboxymethylcellulose 15 g
  • Formula for preparation of 1000 tablets each containing a dose of 100 mg of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (expressed as equivalent to the base):
  •
    Oxalate of 3-[(dimethylamino)methyl]-N-{2- 122.7 g
    [4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-
    2-carboxamide
    Lactose monohydrate 182.3 g
    Magnesium stearate 2.5 g
    Corn starch 75 g
    Maltodextrin 50 g
    Anhydrous colloidal silica 1 g
    Sodium carboxymethylcellulose 15 g
  • Formula for preparation of 1000 tablets each containing a dose of 100 mg of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (expressed as equivalent to the base):
  •
    Naphthalene-1,5-disulfonate of 3-[(dimethylamino)methyl]- 145.4 g
    N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-
    2-carboxamide
    Lactose monohydrate 216.1 g
    Magnesium stearate 2.5 g
    Corn starch 75 g
    Maltodextrin 50 g
    Anhydrous colloidal silica 1 g
    Sodium carboxymethylcellulose 15 g
  • Formula tor preparation of 1000 tablets each containing a dose of 100 mg of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (expressed as equivalent to the base):
  •
    Hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2- 153.9 g
    [4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-
    2-carboxamide
    Lactose monohydrate 228.7 g
    Magnesium stearate 2.5 g
    Corn starch 75 g
    Maltodextrin 50 g
    Anhydrous colloidal silica 1 g
    Sodium carboxymethylcellulose 15 g

Claims (37)

1. A salt of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide of formula (I):
Figure US20170266151A1-20170921-C00005
wherein HA is naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, oxalic acid, benzenesulfonic acid, or sulfuric acid, or a hydrate thereof.
2. The salt of claim 1, which is a salt of formula (Ia):
Figure US20170266151A1-20170921-C00006
wherein HA is naphthalene-1,5-disulfonic acid, naphthalene-sulfonic acid, oxalic acid or benzenesulfonic acid.
3. A crystalline form of the salt of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to claim 1 or 2, wherein HA is naphthalene-1,5-disulfonic acid and wherein the crystalline form has a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2°): 6.87; 10.71; 11.31; 13.97; 18.51; 21.49; 21.84; 24.56.
4. The crystalline form according to claim 3 characterized in that it has a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2°): 6.87; 10.71; 11.31; 13.97; 18.51; 20.71; 21.18; 21.49; 21.84; 22.74; 24.56.
5. The crystalline form according to claim 3 or 4 characterized in that it has a powder X-ray diffraction diagram, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and interplanar spacing d (expressed in Å):
Line no. Angle 2 theta (degrees) Interplanar spacing (Å) 1 6.87 12.861 2 10.71 8.262 3 11.31 7.821 4 13.97 6.341 5 18.51 4.794 6 20.71 4.288 7 21.18 4.194 8 21.49 4.134 9 21.84 4.069 10 22.74 3.910 11 24.56 3.625
6. A crystalline form of the salt of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to claim 1 or 2, wherein HA is naphthalene-1,5-disulfonic acid and wherein the crystalline form has a solid state 13C CP/MAS NMR spectrum exhibiting the following peaks (expressed in ppm±0.2 ppm):
Peak no. Chemical shift (ppm) Δδ ppm (/37.8 ppm) 1 167.9 130.1 2 161.1 123.3 3 158.6 120.8 4 153.8 116.0 5 145.5 107.7 6 142.4 104.6 7 130.3 92.5 8 126.0 88.2 9 122.4 84.6 10 119.6 81.8 11 114.3 76.5 12 64.5 26.7 13 51.2 13.4 14 45.6 7.8 15 44.0 6.2 16 37.8 0.0
7. A crystalline form of the salt of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to claim 1 or 2, wherein HA is naphthalene-2-sulfonic acid and wherein the crystalline form has a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2°): 8.92; 9.33; 10.85; 17.89; 19.79; 21.79; 26.39.
8. The crystalline form according to claim 7 characterized in that it has a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2°): 8.92; 9.33; 10.85; 11.78; 17.89; 19.79; 19.99; 21.79; 25.23; 26.39.
9. The crystalline form according to claim 7 or 8 characterized in that it has a powder X-ray diffraction diagram, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and interplanar spacing d (expressed in Å):
Line no. Angle 2 theta (degrees) Interplanar spacing (Å) 1 8.92 9.917 2 9.33 9.476 3 10.85 8.153 4 11.78 7.515 5 17.89 4.957 6 19.79 4.484 7 19.99 4.440 8 21.79 4.078 9 25.23 3.529 10 26.39 3.376
10. A crystalline form of the salt of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to claim 1 or 2, wherein HA is naphthalene-2-sulfonic acid and wherein the crystalline form has a solid state 13C CP/MAS NMR spectrum exhibiting the following peaks (expressed in ppm±0.2 ppm):
Peak no. Chemical shift (ppm) Δδ ppm (/41.7 ppm) 1 165.7 124.0 2 154.2 112.5 3 141.1 99.4 4 139.5 97.8 5 133.2 91.5 6 128.5 86.8 7 127.6 85.9 8 126.0 84.3 9 124.6 82.9 10 122.4 80.7 11 113.1 71.4 12 64.8 23.1 13 63.2 21.5 14 50.7 9.0 15 47.2 5.5 16 45.5 3.8 17 42.8 1.1 18 41.7 0.0
11. A crystalline form of the salt of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to claim 1 or 2, wherein HA is oxalic acid and wherein the crystalline form has a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2°): 9.11; 9.67; 16.39; 17.73; 18.49; 18.65; 18.79; 21.96; 22.39; 23.39; 26.76; 27.92; 30.72.
12. The crystalline form according to claim 11 characterized in that it has a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2°): 9.11; 9.67; 16.39; 16.56; 17.73; 18.49; 18.65; 18.79; 20.35; 20.85; 21.00; 21.96; 22.39; 23.39; 23.91; 26.22; 26.76; 27.92; 30.72.
13. The crystalline form according to claim 11 or 12 characterized in that it has a powder X-ray diffraction diagram, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and interplanar spacing d (expressed in Å):
Line no. Angle 2 theta (degrees) Interplanar spacing (Å) 1 9.11 9.704 2 9.67 9.142 3 16.39 5.408 4 16.56 5.354 5 17.73 5.004 6 18.49 4.798 7 18.65 4.758 8 18.79 4.721 9 20.35 4.364 10 20.85 4.260 11 21.00 4.229 12 21.96 4.048 13 22.39 3.971 14 23.39 3.804 15 23.91 3.722 16 26.22 3.399 17 26.76 3.332 18 27.92 3.196 19 30.72 2.911
14. A crystalline form of the salt of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to claim 1 or 2, wherein HA is oxalic acid and wherein the crystalline form has a solid state 13C CP/MAS NMR spectrum exhibiting the following peaks (expressed in ppm±0.2 ppm):
Peak no. Chemical shift (ppm) Δδ ppm (/42.9 ppm) 1 168.9 126.0 2 162.6 119.7 3 153.7 110.8 4 146.1 103.2 5 130.0 87.1 6 128.7 85.8 7 127.4 84.5 8 125.8 82.9 9 124.3 81.4 10 123.2 80.3 11 119.8 76.9 12 118.5 75.6 13 114.2 71.3 14 113.5 70.6 15 111.8 68.9 16 65.8 22.9 17 50.9 8.0 18 47.3 4.4 19 42.9 0.0
15. A crystalline form of the salt of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to claim 1 or 2, wherein HA is benzenesulfonic acid and wherein the crystalline form has a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2°): 8.08; 10.03; 10.36; 13.63; 15.00; 16.19; 17.73; 17.90; 18.77; 19.77; 21.98; 22.45.
16. The crystalline form according to claim 15 characterized in that it has a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2°): 8.08; 10.03; 10.36; 11.86; 12.66; 13.63; 15.00; 16.19; 16.39; 16.52; 17.73; 17.90; 18.77; 19.77; 20.20; 20.86; 21.11; 21.98; 22.45; 23.84; 26.13; 26.74; 27.44.
17. The crystalline form according to claim 15 or 16 characterized in that it has a powder X-ray diffraction diagram, measured on a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and interplanar spacing d (expressed in Å):
Line no. Angle 2 theta (degrees) Interplanar spacing (Å) 1 8.08 10.949 2 10.03 8.818 3 10.36 8.539 4 11.86 7.463 5 12.66 6.992 6 13.63 6.498 7 15.00 5.906 8 16.19 5.473 9 16.39 5.407 10 16.52 5.366 11 17.73 5.002 12 17.90 4.954 13 18.77 4.728 14 19.77 4.492 15 20.20 4.395 16 20.86 4.259 17 21.11 4.209 18 21.98 4.043 19 22.45 3.961 20 23.84 3.732 21 26.13 3.411 22 26.74 3.333 23 27.44 3.251
18. A crystalline form of the salt of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to claim 1 or 2, wherein HA is benzenesulfonic acid and wherein the crystalline form has a solid state 13C CP/MAS NMR spectrum exhibiting the following peaks (expressed in ppm±0.2 ppm):
Peak no. Chemical shift (ppm) Δδ ppm (/42.0 ppm) 1 165.5 123.5 2 161.7 119.7 3 152.6 110.6 4 145.9 103.9 5 128.2 86.2 6 126.5 84.5 7 121.6 79.6 8 114.3 72.3 9 111.2 69.2 10 68.4 26.4 11 51.2 9.2 12 44.5 2.5 13 42.0 0.0
The salt of claim 1, which is a salt of formula (Ib):
Figure US20170266151A1-20170921-C00007
wherein HA is sulfuric acid, or a hydrate thereof.
20. A hemipentahydrate crystalline form of the salt according to claim 19 characterized in that it has a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2°): 6.92; 9.01; 11.04; 13.87; 14.24; 14.89; 15.06; 17.34; 18.96; 20.05; 21.49; 24.34; 24.59; 25.19; 25.89.
21. The hemipentahydrate crystalline form according to claim 20 characterized in that it has a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2°): 6.92; 9.01; 11.04; 11.82; 13.87; 14.24; 14.89; 15.06; 17.34; 18.96; 20.05; 20.84; 21.23; 21.49; 22.68; 22.85; 24.34; 24.59; 25.19; 25.89; 28.28.
22. The hemipentahydrate crystalline form according to claim 20 or 21 characterized in that it has a powder X-ray diffraction diagram, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and interplanar spacing d (expressed in Å):
Line no. Angle 2 theta (degrees) Interplanar spacing (Å) 1 6.92 12.782 2 9.01 9.815 3 11.04 8.015 4 11.82 7.489 5 13.87 6.386 6 14.24 6.222 7 14.89 5.949 8 15.06 5.882 9 17.34 5.114 10 18.96 4.681 11 20.05 4.429 12 20.84 4.262 13 21.23 4.185 14 21.49 4.134 15 22.68 3.920 16 22.85 3.892 17 24.34 3.657 18 24.59 3.620 19 25.19 3.535 20 25.89 3.441 21 28.28 3.156
23. A hemipentahydrate crystalline form of the salt according to claim 19 characterized in that it has a solid state 13C CP/MAS NMR spectrum exhibiting the following peaks (expressed in ppm±0.2 ppm):
Peak no. Chemical shift (ppm) Δδ ppm (/38.4 ppm) 1 166.0 127.6 2 159.2 120.8 3 146.8 108.4 4 123.1 84.7 5 121.8 83.4 6 120.7 82.3 7 114.8 76.4 8 112.8 74.4 9 112.1 73.7 10 110.0 71.6 11 107.1 68.7 12 66.7 28.3 13 63.0 24.6 14 49.0 10.6 15 41.7 3.3 16 40.2 1.8 17 38.4 0.0
24. A hemiheptahydrate crystalline form of the hydrogen sulfate or 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to claim 19 characterized in that it has a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2°): 9.99; 10.67; 13.79; 13.92; 14.25; 14.67; 15.18; 16.21; 18.44; 18.82; 20.42; 21.71; 22.47; 23.30; 24.25.
25. The hemiheptahydrate crystalline form according to claim 24 characterized in that it has a powder X-ray diffraction diagram exhibiting the following diffraction lines (Bragg angle 2 theta, expressed in degrees±0.2°): 9.99; 10.67; 12.65; 13.79; 13.92; 14.25; 14.67; 15.18; 16.21; 16.43; 18.44; 18.82; 20.42; 20.76; 21.09; 21.45; 21.71; 22.47; 22.92; 23.30; 23.89; 24.25; 26.02; 26.54.
26. The hemiheptahydrate crystalline form according to claim 24 or 25 characterized in that it has a powder X-ray diffraction diagram, measured using a PANalytical X'Pert Pro MPD diffractometer with an X'Celerator detector, and expressed in terms of line position (Bragg angle 2 theta, expressed in degrees±0.2°) and interplanar spacing d (expressed in Å):
Line no. Angle 2 theta (degrees) Interplanar spacing (Å) 1 9.99 8.838 2 10.67 8.284 3 12.65 6.995 4 13.79 6.418 5 13.92 6.356 6 14.25 6.211 7 14.67 6.032 8 15.18 5.831 9 16.21 5.464 10 16.43 5.389 11 18.44 4.808 12 18.82 4.712 13 20.42 4.345 14 20.76 4.276 15 21.09 4.209 16 21.45 4.140 17 21.71 4.090 18 22.47 3.953 19 22.92 3.877 20 23.30 3.814 21 23.89 3.721 22 24.25 3.667 23 26.02 3.422 24 26.54 3.355
27. A pharmaceutical composition comprising a salt of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to any one of claims 1, 2 or 19 as an active ingredient and one or more pharmaceutically acceptable carriers.
28. A pharmaceutical composition comprising a crystalline form of a salt of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to any one of claims 3 to 18 or 20 to 26 as an active ingredient and one or more pharmaceutically acceptable carriers.
29. The pharmaceutical composition according to claim 27 or 28 for use in the treatment of cancer.
30. The pharmaceutical composition according to any one of claims 27 to 29 wherein the cancer is a carcinoma, a tumor, a neoplasm, a lymphoma, a melanoma, a glioma, a sarcoma or a blastoma.
31. A method for preparing a crystalline form of a salt of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to any one of claims 3 to 18, wherein the 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide is crystallized in the presence of naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, oxalic acid or benzenesulfonic acid in a polar medium.
32. The method according to claim 31, wherein the polar medium consists of one or more solvents chosen from among water, alcohols, ketones, nitriles and esters.
33. The method according to claim 31, wherein the polar medium is a binary mixture, one of the components of which is water.
34. The method according to claim 31, wherein the polar medium is a binary mixture chosen from among: acetone/water, ethanol/water, isopropanol/water and methylethylketone/water.
35. A method for preparing a hydrated crystalline form of the hydrogen sulfate of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide according to any one of claims 20 to 26, in which the 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide is crystallized in a polar medium in the presence of sulfuric acid.
36. The method according to claim 35, wherein the polar medium consists of one or more solvents chosen from among water, ketones, nitriles and esters.
37. The method according to claim 35, wherein the polar medium is a binary mixture, one of the components of which is water.
US15/508,609 2014-09-03 2015-09-03 Novel salts of 3-[(DIMETHYLAMINO)METHYL]-N--1-BENZOFURAN-2-CARBOXAMIDE, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same Abandoned US20170266151A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR1458224 2014-09-03
FR1458224A FR3025197B1 (en) 2014-09-03 2014-09-03 NOVEL SALT OF 3 - [(DIMETHYLAMINO) METHYL] -N- {2- [4- (HYDROXYCARBAMOYL) PHENOXY] ETHYL} -1-BENZOFURAN-2-CARBOXAMIDE, ASSOCIATED CRYSTALLINE FORMS, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF CONTAIN
FR1458215A FR3025196B1 (en) 2014-09-03 2014-09-03 NOVEL 3 - [(DIMETHYLAMINO) METHYL] -N- {2- [4- (HYDROXYCARBAMOYL) PHENOXY] ETHYL} -1-BENZOFURAN-2-CARBOXAMIDE SALTS, ASSOCIATED CRYSTALLINE FORMS, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF CONTAIN
FR1458215 2014-09-03
PCT/US2015/048243 WO2016036910A1 (en) 2014-09-03 2015-09-03 Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/048243 A-371-Of-International WO2016036910A1 (en) 2014-09-03 2015-09-03 Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/676,911 Continuation US10898461B2 (en) 2014-09-03 2019-11-07 Salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl) phenoxy]ethyli-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same

Publications (1)

Publication Number Publication Date
US20170266151A1 true US20170266151A1 (en) 2017-09-21

Family

ID=54186276

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/508,609 Abandoned US20170266151A1 (en) 2014-09-03 2015-09-03 Novel salts of 3-[(DIMETHYLAMINO)METHYL]-N--1-BENZOFURAN-2-CARBOXAMIDE, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
US16/676,911 Active US10898461B2 (en) 2014-09-03 2019-11-07 Salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl) phenoxy]ethyli-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/676,911 Active US10898461B2 (en) 2014-09-03 2019-11-07 Salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl) phenoxy]ethyli-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same

Country Status (10)

Country Link
US (2) US20170266151A1 (en)
EP (1) EP3189040B1 (en)
JP (1) JP2017530106A (en)
KR (1) KR20170043648A (en)
CN (1) CN107001307A (en)
AU (1) AU2015311905B2 (en)
CA (1) CA2960044A1 (en)
MX (1) MX2017002858A (en)
SG (2) SG10201901916WA (en)
WO (1) WO2016036910A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001307A (en) 2014-09-03 2017-08-01 药品循环有限责任公司 Novel salt, relevant crystal form, methods for making them and the pharmaceutical composition comprising it of the formamide of 3 [(dimethylamino) methyl] N { 2 [4 (Hydroxycarboamoyl) phenoxy group] ethyl } 1 benzofuran 2
US20240279195A1 (en) * 2021-06-10 2024-08-22 Teva Pharmaceuticals International Gmbh Solid state forms of abexinostat and process for preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110311624A1 (en) * 2009-04-17 2011-12-22 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
GB0020721D0 (en) 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
DK1611088T3 (en) 2003-04-07 2009-10-19 Pharmacyclics Inc Hydroxymates as therapeutic agents
EP1698623B1 (en) 2003-12-25 2015-04-15 Eisai R&D Management Co., Ltd. Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these
US8702670B2 (en) 2004-06-30 2014-04-22 Mcneil-Ppc, Inc. Intravaginal device with controlled expansion
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
WO2011036647A1 (en) 2009-09-24 2011-03-31 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
MX2013010329A (en) * 2011-03-09 2014-03-12 Sverker Jern Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors.
FR2977492B1 (en) 2011-07-04 2013-07-05 Servier Lab NOVEL ASSOCIATION BETWEEN N-HYDROXY-4- {2- [3- (N, N-DIMETHYLAMINOMETHYL) BENZOFURAN-2-YLCARBONYLAMINO] ETHOXY} BENZAMIDE AND FOLFOX
WO2013039956A2 (en) 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating mood disorders
CN102531964B (en) * 2011-10-10 2014-06-11 华东理工大学 Dicarboxylic acid derivatives with anti-tumor effect and preparation method thereof
FR3002733B1 (en) * 2013-03-04 2015-08-14 Servier Lab NOVEL SALT OF THE ABEXINOSTAT, THE CRYSTALLINE FORM ASSOCIATED WITH THEM, THE PROCESS FOR PREPARING THEM AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN107001307A (en) 2014-09-03 2017-08-01 药品循环有限责任公司 Novel salt, relevant crystal form, methods for making them and the pharmaceutical composition comprising it of the formamide of 3 [(dimethylamino) methyl] N { 2 [4 (Hydroxycarboamoyl) phenoxy group] ethyl } 1 benzofuran 2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110311624A1 (en) * 2009-04-17 2011-12-22 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof

Also Published As

Publication number Publication date
EP3189040A1 (en) 2017-07-12
JP2017530106A (en) 2017-10-12
CA2960044A1 (en) 2016-03-10
KR20170043648A (en) 2017-04-21
US20200069637A1 (en) 2020-03-05
CN107001307A (en) 2017-08-01
WO2016036910A1 (en) 2016-03-10
US10898461B2 (en) 2021-01-26
AU2015311905A1 (en) 2017-03-23
MX2017002858A (en) 2017-10-24
EP3189040B1 (en) 2020-07-29
SG10201901916WA (en) 2019-04-29
SG11201701674RA (en) 2017-04-27
AU2015311905B2 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
AU2018202881B2 (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
RU2663663C2 (en) Salt of omecamtiv mecarbil and process for preparing same
RU2639149C2 (en) Crystalline polymorphyl of 4-[5-(pyridine-4-yl)-1h-1,2,4-triazol-3-yl]-pyridine-2-carbonitrile and method of its obtaining
RU2704795C2 (en) Crystalline form of inhibitor bisulphate jak and method for production thereof
US10898461B2 (en) Salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl) phenoxy]ethyli-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
WO2018117267A1 (en) Salt of substituted piperidine compound
JP2022506137A (en) Novel salts of BCL-2 inhibitors, related crystalline forms, methods of preparation thereof and pharmaceutical compositions containing them.
PT2532651E (en) Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide hydrochloride and its free base as well as the pharmaceutical compositions containing them
FR3025196B1 (en) NOVEL 3 - [(DIMETHYLAMINO) METHYL] -N- {2- [4- (HYDROXYCARBAMOYL) PHENOXY] ETHYL} -1-BENZOFURAN-2-CARBOXAMIDE SALTS, ASSOCIATED CRYSTALLINE FORMS, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF CONTAIN
FR3025197B1 (en) NOVEL SALT OF 3 - [(DIMETHYLAMINO) METHYL] -N- {2- [4- (HYDROXYCARBAMOYL) PHENOXY] ETHYL} -1-BENZOFURAN-2-CARBOXAMIDE, ASSOCIATED CRYSTALLINE FORMS, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF CONTAIN
KR102306524B1 (en) Novel abexinostat salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
JP6985137B2 (en) Crystal form of sulfonamide compound
NZ712380B2 (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
SK50262014U1 (en) Pharmaceutically acceptable salts of 2-chloro-N-(4-chloro-3- (pyridin-2-yl)-phenyl)-4-(methylsulfonyl)benzamide

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE